Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Diagnosis and management of multiple myeloma: a review
Importance Multiple myeloma is a hematologic malignancy characterized by presence of
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …
abnormal clonal plasma cells in the bone marrow, with potential for uncontrolled growth …
Multiple myeloma current treatment algorithms
The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …
Triplet therapy, transplantation, and maintenance until progression in myeloma
Background In patients with newly diagnosed multiple myeloma, the effect of adding
autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib …
autologous stem-cell transplantation (ASCT) to triplet therapy (lenalidomide, bortezomib …
Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the …
M D'agostino, DA Cairns, JJ Lahuerta… - Journal of clinical …, 2022 - ascopubs.org
PURPOSE Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …
outcomes, and approximately 60% of them are at intermediate-risk according to the Revised …
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and …
F Gay, P Musto, D Rota-Scalabrini, L Bertamini… - The Lancet …, 2021 - thelancet.com
Background Bortezomib-based induction followed by high-dose melphalan (200 mg/m 2)
and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with …
and autologous stem-cell transplantation (MEL200-ASCT) and maintenance treatment with …
Genomic profiling for clinical decision making in lymphoid neoplasms
With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
sequencing technologies, the genomic features of most lymphoid neoplasms have been …
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple …
Background Anti-CD38 monoclonal antibodies have consistently shown increased efficacy
when added to standard of care for patients with multiple myeloma. We aimed to assess the …
when added to standard of care for patients with multiple myeloma. We aimed to assess the …
[HTML][HTML] Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Since the publication of the article entitled “Multiple Myeloma: EHA-ESMO Clinical Practice
Guidelines for Diagnosis, Treatment and Follow-up”(HemaSphere. 2021; 5: e528) …
Guidelines for Diagnosis, Treatment and Follow-up”(HemaSphere. 2021; 5: e528) …
Genomic classification and individualized prognosis in multiple myeloma
PURPOSE Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are
heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS …
heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS …
Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk …
PURPOSE The multicenter OPTIMUM (MUKnine) phase II trial investigated daratumumab,
low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) …
low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) …